IMPROVED CELL COMPOSITIONS AND METHODS FOR CANCER THERAPY
1 Assignment
0 Petitions
Accused Products
Abstract
Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
1 Citation
66 Claims
-
1-44. -44. (canceled)
-
45. A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an isolated NTB-A ectodomain or an agonist thereof, wherein said subject is afflicted with a tumor selected from the group consisting of:
- a tumor characterized by lack of substantial NTB-A surface expression, a solid tumor and a tumor characterized by surface expression of CD137.
- View Dependent Claims (46, 47, 48, 49)
- 50. A method of reducing or inhibiting T cell death or for treating or preventing cytopenia, comprising contacting T cells with an effective amount of an isolated NTB-A ectodomain or an agonist thereof.
- 58. A method for preparing a cell composition, comprising incubating a T cell containing cell population ex vivo with an effective amount of an isolated NTB-A ectodomain or an agonist thereof, and further comprising providing the cell population with a T cell receptor (TCR) stimulation.
Specification